Enliven Therapeutics, Inc.
ELVN
$18.71
-$0.03-0.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.14% | -24.36% | -37.97% | -60.68% | -82.08% |
| Total Depreciation and Amortization | 0.97% | 6.73% | 11.31% | 18.11% | 27.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 123.19% | 132.75% | 87.30% | 44.00% | 114.38% |
| Change in Net Operating Assets | -146.06% | -424.13% | 141.45% | 92.54% | 192.69% |
| Cash from Operations | -15.95% | -19.46% | -20.27% | -51.99% | -49.87% |
| Capital Expenditure | 68.12% | 70.47% | 75.42% | 77.78% | 69.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 89.98% | 75.75% | 101.08% | 68.06% | -- |
| Cash from Investing | 89.96% | 75.75% | 101.05% | 68.08% | -36,930.29% |
| Total Debt Issued | -- | -- | -- | -200.00% | -200.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -82.88% | -45.33% | -61.69% | 208.79% | 207.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 95.91% | 80.52% |
| Cash from Financing | -50.49% | -43.16% | -59.76% | -60.53% | -62.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 66.76% | -2.56% | 317.46% | -186.73% | -174.36% |